This is a clinical trial (a type of research study) designed to describe the efficacy (effectiveness) and toxicity (safety) of a new medical treatment, NESP (Novel Erythropoiesis Stimulating Protein). This study will be offered to patients with cervical cancer undergoing a combination of chemotherapy and radiation. This treatment may lower your red blood cells. The use of NESP may stimulate the body to produce more red blood cells. Our hypothesis is that higher red blood cells will be beneficial to the patient during treatment for cervical cancer.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Female

Accepts Healthy Volunteers

Criteria

• Consent form completed and signed
• Hemoglobin between 9-13 g/dL
• Life expectancy of at least 4 months
• Karnofsky Performance Status =/> 70
• No evidence of hemolysis, GI bleeding, or bleeding due to recent surgery
• Adequate renal and liver function